At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Post-Market Trading 01-08 19:12:47 EST
1.80
-0.07
-3.74%
盘后1.84
+0.04+2.13%
18:37 EST
High1.86
Low1.77
Vol591.95K
Open1.86
D1 Closing1.87
Amplitude4.81%
Mkt Cap49.53M
Tradable Cap48.19M
Total Shares27.52M
T/O1.07M
T/O Rate2.21%
Tradable Shares26.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Iterum Therapeutics Plc Files for Offering of up to $25 Mln of Ordinary Shares - SEC Filing
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.